Amyloidosis patients are expected to see some significant breakthroughs in treatment over the next three years, reducing side effects and possibly the need for organ transplants, research by healthcare market analysis specialist GlobalData has found. Amyloidosis occurs when a build-up of proteins forms an abnormally folded structure within the body's cells and tissues, which then forms an insoluble deposit in a particular organ. Although amyloidosis is a severe and life-threatening disease, the market currently lacks an approved therapy. The current therapeutic approaches towards amyloidosis are non-specific, invasive, often toxic and sometimes ineffective. The chemotherapeutic agents prescribed for the treatment of AL amyloidosis have poor safety profiles and sometimes cause patients to suffer more from side effects than the actual symptoms of the disease. Treatment with... read more